Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (DBCOND0029923)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02530034	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	No drug interventions	treatment	1	active_not_recruiting
NCT04188405	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia	Decitabine Ponatinib Venetoclax	treatment	2	active_not_recruiting
NCT03576547	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Dexamethasone Ponatinib Rituximab Venetoclax	treatment	1 / 2	completed
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Fludarabine	treatment	1	suspended
NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	Aldesleukin Busulfan Fludarabine Natural Killer Cell	treatment	1 / 2	completed
NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	Cyclophosphamide Fludarabine Mechlorethamine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Adavosertib Belinostat	treatment	1	terminated
NCT01424982	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia	Cortisone Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Doxorubicin Methopterin Methotrexate Ponatinib Prednisone Rituximab Sulfate ion Vincristine	treatment	2	active_not_recruiting
NCT03589729	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Cladribine Cytarabine Dexrazoxane Gemtuzumab ozogamicin Idarubicin	supportive_care	2	recruiting
NCT01858740	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	Fludarabine Methopterin Methotrexate Tacrolimus Thiotepa Tromethamine	treatment	2	completed
NCT03147612	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia	Blinatumomab Cyclophosphamide Cytarabine Filgrastim Methopterin Methotrexate Muromonab Pegfilgrastim Ponatinib Rituximab Vincristine	treatment	2	active_not_recruiting
NCT02311998	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML	Bosutinib Inotuzumab ozogamicin	treatment	1 / 2	completed
NCT00390793	Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.	Cortisone Cyclophosphamide Cytarabine Dasatinib Daunorubicin Dexamethasone Doxorubicin Methopterin Methotrexate Prednisone Vincristine	treatment	2	completed
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	Cyclophosphamide Fludarabine Methopterin Methotrexate Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT02728700	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT	Mycophenolate mofetil Sirolimus	prevention	1	terminated
NCT00068718	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant	Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT01428635	Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy	Eltrombopag	supportive_care	2 / 3	completed
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT03263572	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	Blinatumomab Cytarabine Methopterin Methotrexate Muromonab Ponatinib	treatment	2	recruiting
NCT02960646	Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Cyclophosphamide Filgrastim Fludarabine Mechlorethamine Rituximab Tacrolimus	treatment	1	completed
NCT04526795	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia	Cytarabine Fludarabine Pegcrisantaspase	treatment	1	active_not_recruiting
NCT02115295	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Cladribine Cytarabine Gilteritinib Idarubicin Midostaurin Venetoclax	treatment	2	recruiting